---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-074628"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:03:58.997941+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences exchanges 8.3M common shares for Series B non-voting convertible preferred

## Summary
- 8,300,000 common shares exchanged for 8,300 Series B Preferred convertible into 20,580,000 common shares.
- Exchange closes March 25, 2024; Series B has no voting rights except on amendments to its preferences.
- Post-exchange common outstanding: 95,613,396; Series A Preferred convertible into 18,616,250 common shares.
- Issued under Section 3(a)(9) exemption; no registration required.

## SEC filing metadata
- accession: 0001193125-24-074628
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312524074628/0001193125-24-074628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312524074628/d796451d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-074628
- JSON: https://secwatch.observer/filing/0001193125-24-074628.json
- Plain text: https://secwatch.observer/filing/0001193125-24-074628.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.